May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Standard vs. Reduced Dose Systemic Bevacizumab (Avastin®) for the Treatment of Neovascular Age–Related Macular Degeneration
Author Affiliations & Notes
  • S.M. Michels
    Medical University of Vienna, Vienna, Austria
    Ophthalmology,
  • P.J. Rosenfeld
    Ophthalmology, Bascom Palmer Eye Institute, University of Miami Medical School, FL
  • W. Geitzenauer
    Medical University of Vienna, Vienna, Austria
    Ophthalmology,
  • F. Prager
    Medical University of Vienna, Vienna, Austria
    Ophthalmology,
  • A. Rosin
    Medical University of Vienna, Vienna, Austria
    Ophthalmology,
  • G. Kornek
    Medical University of Vienna, Vienna, Austria
    Internal Medicine–Oncology,
  • L. Vormittag
    Medical University of Vienna, Vienna, Austria
    Internal Medicine–Oncology,
  • U. Schmidt–Erfurth
    Medical University of Vienna, Vienna, Austria
    Ophthalmology,
  • Footnotes
    Commercial Relationships  S.M. Michels, None; P.J. Rosenfeld, None; W. Geitzenauer, None; F. Prager, None; A. Rosin, None; G. Kornek, None; L. Vormittag, None; U. Schmidt–Erfurth, None.
  • Footnotes
    Support  German Research Foundation (DFG) MI 742
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5231. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.M. Michels, P.J. Rosenfeld, W. Geitzenauer, F. Prager, A. Rosin, G. Kornek, L. Vormittag, U. Schmidt–Erfurth; Standard vs. Reduced Dose Systemic Bevacizumab (Avastin®) for the Treatment of Neovascular Age–Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5231.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the initial treatment responses following 2.5 or 5 mg/kg intravenous bevacizumab in patients with neovascular age–related macular degeneration (AMD).

Methods: : In a prospective cohort study, 14 eyes (8 patients) were treated with 5 mg/kg and 12 eyes (7 patients) with 2.5 mg/kg intravenous bevacizumab. All patients received 3 i.v. infusions at 2 week intervals and completed 3 months follow–up. Patients were monitored at least every 4 weeks by ETDRS visual acuity, optical coherence tomography (OCT), and fluorescein angiography (FA).

Results: : Both groups showed a response to treatment after the first infusion. At day 7, mean visual acuity (VA) increased from 56.3 letters at baseline to 60.4 letters in the 5 mg/kg group and the mean central retinal thickness, as measured by OCT, decreased by 83 µm. In the 2.5 mg/kg group, the mean VA increased from 59.8 letters to 65.5 letters and the mean OCT central retinal thickness (CRT) decreased by 106 µm. At 3 months follow–up, VA improved by 8 letters compared to baseline in the 5 mg/kg group and by 11 letters in the 2.5 mg/kg group. CRT was reduced by 121µm in the 5 mg/kg group and 138µm in the 2.5 mg/kg group. In all patients, leakage documented by FA was absent or significantly reduced by 3 months follow–up.

Conclusions: : Initial treatment responses to 2.5 and 5mg/kg bevacizumab in patients with neovascular AMD appear comparable. Further follow–up is required to evaluate durability and long–term safety of both treatment regimens.

Keywords: age-related macular degeneration • choroid: neovascularization • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×